Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer

NCT: NCT07492381 · NOT_YET_RECRUITING

NCT IDNCT07492381
StatusNOT_YET_RECRUITING
Start Date2026-04
Completion2029-12

Brief Summary

The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.

Frequently Asked Questions

What is A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer?

A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer is a clinical trial registered under NCT07492381. Current status: NOT_YET_RECRUITING.

What is the status of NCT07492381?

The current status of NCT07492381 (A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer) is: NOT_YET_RECRUITING.

When did A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer start?

A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer started on 2026-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑